All In Biotech

Drug Trial Radar · NCT03238235

Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular Dystrophy

A Randomised, Double Blind, Placebo Controlled Study to Evaluate the Micro-macroscopic Effects on Muscles, the Safety and Tolerability, and the Efficacy of Givinostat in Patients With Becker Muscular Dystrophy (BMD)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

51

Actual

Start

Jan 9, 2018

Primary completion

Mar 19, 2021

Study completion Mar 19, 2021

Sponsor

Lead sponsor
ItalfarmacoIndustry
Sponsor type
Industry
First posted
Aug 3, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Objectives: Primary objective: to establish the histological effects of Givinostat versus placebo administered over 12 months. Secondary Objectives: * To establish the macroscopic muscle effects of Givinostat versus placebo administered over 12 months assessed by Magnetic Resonance Imaging (MRI)/Magnetic Resonance Spectroscopy (MRS). * To determine the other histological effects of Givinostat versus placebo administered over 12 months. * To establish the efficacy of Givinostat versus placebo administered chronically over 12 months in slowing disease progression. * To assess the safety and tolerability of Givinostat versus placebo administered chronically. * To evaluate the pharmacokinetic (PK) profile of Givinostat administered chronically in the target population. * To evaluate the impact of Givinostat versus placebo administered chronically on quality of life and activities of daily living.

Conditions

  • Becker Muscular Dystrophy

Interventions

  • GivinostatDrug

    suspension of Givinostat (10 mg/mL)

  • PlaceboDrug

    suspension manufactured to mimic Givinostat

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline to Visit 11 in Total Fibrosis (%) on Log Scale, Comparing the Histology of Muscle BiopsiesTime frame: after 12 months of treatment (at Visit 11)

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, UOS

    Milan, Italy

  • Leiden University Medical Center LUMC

    Leiden, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.